Regulation in the face of uncertainty: The evidence on electronic nicotine delivery systems (e-cigarettes)

Risk Management and Healthcare Policy

Volumn 8, Issue , 2015, Pages 157-167

  Farsalinos, Konstantinos E ^a,b   Le Houezec, Jacques ^c,d  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d INSERM   (France)

Author keywords

Electronic cigarettes; Nicotine; Precautionary principle; Regulation; Smoking; Tobacco harm reduction

Indexed keywords

NICOTINE;

CLINICAL EFFECTIVENESS; DEVICE SAFETY; DRUG DELIVERY DEVICE; ELECTRONIC CIGARETTE; GOVERNMENT REGULATION; HUMAN; MEDICAL DEVICE REGULATION; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRODUCT SAFETY; REIMBURSEMENT; REVIEW; RISK REDUCTION; SMOKING; SMOKING CESSATION; TOBACCO CONSUMPTION; TOBACCO DEPENDENCE; TOBACCO INDUSTRY;

EID: 84943427430     PISSN: None     EISSN: 11791594     Source Type: Journal    
DOI: 10.2147/RMHP.S62116     Document Type: Review

References (93)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994
2. World Health Organization. International Classification of Diseases, 10th Revision (ICD-10). Geneva, Switzerland: World Health Organization; 1992
3. George TP, Weinberger AH. Monoamine oxidase inhibition for tobacco pharmacotherapy. Clin Pharmacol Ther. 2008;83(4):619–621
4. Berlin I, Saïd S, Spreux-Varoquaux O, Olivares R, Launay JM, Puech AJ. Monoamine oxidase A and B activities in heavy smokers. Biol Psychiatr. 1995;38:756–761
5. Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362(24): 2295–2303
6. World Health Organization. WHO Global Report: Mortality Attributable to Tobacco. Geneva, Switzerland: WHO; 2012. Available from: http://www.who.int/tobacco/publications/surveillance/rep_mortality_attributable/en/index.html. Accessed July 20, 2015
7. Jha P. Avoidable global cancer deaths and total deaths from smoking. Nat Rev Cancer. 2009;9(9):655–664
8. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observation on male British doctors. BMJ. 2004; 328(7455):1519
9. Pirie K, Peto R, Reeves GK, Green J, Beral V; Million Women Study Collaborators. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet. 2013;381(9861):133–141
10. Le Houezec J. Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review. Int J Tuberc Lung Dis. 2003;7:811–819
11. Royal College of Physicians. Harm Reduction in Nicotine Addiction. London, UK: Royal College of Physicians; 2007
12. Cummings KM, Hyland A, Giovino GA, Hastrup JL, Bauer JE, Bansal MA. Are smokers adequately informed about the health risks of smoking and medicinal nicotine? Nicotine Tob Res. 2004;6(Suppl 3):S333–S340
13. Siahpush M, McNeill A, Borland R, Fong G. Socioeconomic variations in nicotine dependence, self-efficacy and intention to quit across four countries: findings from the International Tobacco Control Policy Evaluation Survey. Tob Control. 2006;15(Suppl III):iii71–iii75
14. Le Houezec J, McNeill A, Britton J. Tobacco, nicotine and harm reduction. Drug Alcohol Rev. 2011;30(2):119–123
15. Royal College of Physicians. Ending Tobacco Smoking in Britain. Radical Strategies for Prevention and Harm Reduction in Nicotine Addiction. London, UK: Royal College of Physicians; 2008. Available from: http://www.rcplondon.ac.uk/publications/ending-tobacco-smoking-britain. Accessed July 20, 2015
16. Benowitz NL. Smokeless tobacco as a nicotine delivery device: harm or harm reduction? Clin Pharmacol Ther. 2011;90(4):491–493
17. Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest. 1996;109(2):438–445
18. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol. 1997;29(7):1422–1431
19. Medicines and Healthcare Products Regulatory Agency. Nicotine Replacement Therapy (NRT) and harm reduction. London, UK: Medicines and Healthcare Products Regulatory Agency; 2010. Available from: https://www.gov.uk/drug-safety-update/nicotine-replacement-therapy-and-harm-reduction. Accessed January 20, 2014
20. National Institute for Health and Care Excellence. Tobacco-Harm-Reduction Approaches to Smoking: Guidance. London, UK: National Institute for Health and Care Excellence; 2013. Available from: http://www.nice.org.uk/guidance/PH45. Accessed January 20, 2014
21. Gray N, Boyle P. The future of the nicotine-addiction market. Lancet. 2003;362(9387):845–846
22. King BA, Alam S, Promoff G, Arrazola R, Dube SR. Awareness and ever-use of electronic cigarettes among US. adults, 2010–2011. Nicotine Tob Res. 2013;15(9):1623–1627
23. Dockrell M, Morrison R, Bauld L, McNeill A. E-cigarettes: prevalence and attitudes in Great Britain. Nicotine Tob Res. 2013;15(10):1737–1744
24. Adkison SE, O’Connor RJ, Bansal-Travers M, et al. Electronic nicotine delivery systems: international tobacco control four-country survey. Am J Prev Med. 2013;44(3):207–215
25. European Commission. Eurobarometer 385. Attitudes of Europeans towards Tobacco. Brussels, Luxembourg: European Commission; 2012. Available from: http://ec.europa.eu/public_opinion/archives/ebs/ebs_385_en.pdf. Accessed July 13, 2015
26. Zhu SH, Sun JY, Bonnevie E, et al. Four hundred and sixty brands of e-cigarettes and counting: implications for product regulation. Tob Control. 2014;23(Suppl 3):iii3–iii9
27. Farsalinos KE, Romagna G, Tsiapras D, Kyrzopoulos S, Spyrou A, Voudris V. Impact of flavour variability on electronic cigarette use experience: an internet survey. Int J Environ Res Public Health. 2013; 10(12):7272–7282
28. Buchhalter AR, Acosta MC, Evans SE, Breland AB, Eissenberg T. Tobacco abstinence symptom suppression: the role played by the smoking-related stimuli that are delivered by denicotinized cigarettes. Addiction. 2005;100(4):550–559
29. Vansickel AR, Cobb CO, Weaver MF, Eissenberg TE. A clinical laboratory model for evaluating the acute effects of electronic “cigarettes”: nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1945–1953
30. Bullen C, McRobbie H, Thornley S, Glover M, Lin R, Laugesen M. Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tob Control. 2010;19(2):98–103
31. Farsalinos KE, Spyrou A, Tsimopoulou K, Stefopoulos C, Romagna G, Voudris V. Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices. Sci Rep. 2014;4:4133
32. Farsalinos KE, Spyrou A, Stefopoulos C, et al. Nicotine absorption from electronic cigarette use: comparison between experienced consumers (vapers) and naïve users (smokers). Sci Rep. 2015;5:11269
33. Fairchild AL, Bayer R, Colgrove J. The renormalization of smoking? E-cigarettes and the tobacco “endgame”. N Engl J Med. 2014;370(4): 293–295
34. Jollye L. E-cigarettes in the UK: a more inclusive debate is needed. Lancet. 2014;384(9954):1576
35. Harris JK, Moreland-Russell S, Choucair B, Mansour R, Staub M, Simmons K. Tweeting for and against public health policy: response to the Chicago Department of Public Health’s electronic cigarette Twitter campaign. J Med Internet Res. 2014;16(10):e238
36. McKee M, Chapman S, Daube M, Glantz S. The debate on electronic cigarettes. Lancet. 2014;384(9960):2107
37. Etter JF. E-cigarettes: methodological and ideological issues and research priorities. BMC Med. 2015;13:32
38. McNeill A, Etter JF, Farsalinos K, Hajek P, le Houezec J, McRobbie H. A critique of a World Health Organization-commissioned report and associated paper on electronic cigarettes. Addiction. 2014;109(12): 2128–2134
39. Farsalinos KE, Polosa R. Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Saf. 2014;5(2):67–86
40. Grana R, Benowitz N, Glantz SA. E-cigarettes: a scientific review. Circulation. 2014;129(19):1972–1986
41. Hajek P, Etter JF, Benowitz N, Eissenberg T, McRobbie H. Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction. 2014;109(11):1801–1810
42. Tremblay MC, Pluye P, Gore G, Granikov V, Filion KB, Eisenberg MJ. Regulation profiles of e-cigarettes in the United States: a critical review with qualitative synthesis. BMC Med. 2015;13(1):130
43. Gourdet CK, Chriqui JF, Chaloupka FJ. A baseline understanding of state laws governing e-cigarettes. Tob Control. 2014;23(Suppl 3):iii37–iii40
44. Farsalinos KE, Romagna G, Tsiapras D, Kyrzopoulos S, Voudris V. Characteristics, perceived side effects and benefits of electronic cigarette use: a worldwide survey of more than 19,000 consumers. Int J Environ Res Public Health. 2014;11(4):4356–4373
45. Grandjean P, Bailar JC, Gee D, et al. Implications of the Precautionary Principle in research and policy-making. Am J Ind Med. 2004;45(4): 382–385
46. Rio Declaration on Environment and Development. Stockholm, Sweden: United Nations; 1992. Publication E.73.II.A.14. Available from: http://www.un.org/documents/ga/conf151/aconf15126-1annex1.htm. Accessed July 23, 2015
47. European Commission. Communication from the Commission on the Precautionary Principle. COM(2000) 1. Brussels, 2000. Brussels, Luxembourg: European Commission. Available from: http://ec.europa.eu/dgs/health_consumer/library/pub/pub07_en.pdf. Accessed July 22, 2015
48. Peterson M. The precautionary principle should not be used as a basis for decision-making. Talking point on the precautionary principle. EMBO Rep. 2007;8(4):305–308
49. Goldstein BD, Carruth RS. Implications of the Precautionary Principle: is it a threat to science? Int J Occup Med Environ Health. 2004;17(1): 153–161
50. ter Meulen RH. The ethical basis of the precautionary principle in health care decision making. Toxicol Appl Pharmacol. 2005;207(2 Suppl): 663–667
51. Peterson M. The precautionary principle is incoherent. Risk Anal. 2006;26(3):595–601
52. Bell K, Stimson GV. Nicotine: science, regulation and policy. Int J Drug Policy. 2015;26(6):533–535
53. Esterl M. Got a light –er charger? Big tobacco’s latest buzz. Wall Street Journal. 2012. Available from: http://www.wsj.com/articles/SB10001424052702304723304577365723851497152. Accessed July 23, 2015
54. Regan AK, Promoff G, Dube SR, Arrazola R. Electronic nicotine delivery systems: adult use and awareness of the ‘e-cigarette’ in the USA. Tob Control. 2013;22(1):19–23
55. Arrazola RA, Singh T, Corey CG, et al. Centers for Disease Control and Prevention (CDC). Tobacco use among middle and high school students –United States, 2011–2014. MMWR Morb Mortal Wkly Rep. 2015;64(14):381–385
56. Dutra LM, Glantz SA. Electronic cigarettes and conventional cigarette use among US adolescents: a cross-sectional study. JAMA Pediatr. 2014;168(7):610–617
57. Farsalinos KE, Polosa R. Youth tobacco use and electronic cigarettes. JAMA Pediatr. 2014;168(8):775
58. Amato MS, Boyle RG, Levy D. How to define e-cigarette prevalence? Finding clues in the use frequency distribution. Tob Control. Epub June 17, 2015
59. Action on Smoking and Health UK. Use of Electronic Cigarettes (Vapourisers) among Adults in Great Britain. London, UK: Action on Smoking and Health UK; 2015. Available from: http://www.ash.org.uk/files/documents/ASH_891.pdf. Accessed July 23, 2015
60. Moore G, Hewitt G, Evans J, et al. Electronic-cigarette use among young people in Wales: evidence from two cross-sectional surveys. BMJ Open. 2015;5(4):e007072
61. Lee S, Grana RA, Glantz SA. Electronic cigarette use among Korean adolescents: a cross-sectional study of market penetration, dual use, and relationship to quit attempts and former smoking. J Adolesc Health. 2014;54(6):684–690
62. University of California San Francisco. Electronic Cigarettes: New Route to Smoking Addiction for Adolescents. San Francisco, CA: University of California. Available from: http://www.ucsf.edu/news/2013/11/110416/electronic-cigarettes-new-route-smoking-addiction-adolescents. Accessed July 23, 2015
63. Al-Delaimy WK, Myers MG, Leas EC, Strong DR, Hofstetter CR. E- cigarette use in the past and quitting behavior in the future: a population- based study. Am J Public Health. 2015;105(6):1213–1219
64. Vickerman KA, Carpenter KM, Altman T, Nash CM, Zbikowski SM. Use of electronic cigarettes among state tobacco cessation quitline callers. Nicotine Tob Res. 2013;15(10):1787–1791
65. Alere blog. E-Cigs: Are They A Problem Or A Solution? Available from: http://blog.alerewellbeing.com/bid/288222/E-Cigs-Are-They-A-Problem-Or-A-Solution. Accessed July 23, 2015
66. Varlet V, Farsalinos K, Augsburger M, Thomas A, Etter JF. Toxicity assessment of refill liquids for electronic cigarettes. Int J Environ Res Public Health. 2015;12(5):4796–4815
67. Farsalinos KE, Voudris V, Poulas K. Are metals emitted from electronic cigarettes a reason for health concern? A risk-assessment analysis of currently available literature. Int J Environ Res Public Health. 2015;12(5):5215–5232
68. Farsalinos KE, Kistler KA, Gillman G, Voudris V. Evaluation of electronic cigarette liquids and aerosol for the presence of selected inhalation toxins. Nicotine Tob Res. 2015;17(2):168–174
69. Goniewicz ML, Knysak J, Gawron M, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control. 2014;23(2):133–139
70. Jensen RP, Luo W, Pankow JF, Strongin RM, Peyton DH. Hidden formaldehyde in e-cigarette aerosols. N Engl J Med. 2015;372(4):392–394
71. Nitzkin JL, Farsalinos K, Siegel M. More on hidden formaldehyde in e-cigarette aerosols. N Engl J Med. 2015;372(16):1575
72. Farsalinos KE, Voudris V, Poulas K. E-cigarettes generate high levels of aldehydes only in ‘dry puff’ conditions. Addiction. 2015;110(8): 1352–1356
73. Tverdal A, Bjartveit K. Health consequences of reduced daily cigarette consumption. Tob Control. 2006;15(6):472–480
74. Hart C, Gruer L, Bauld L. Does smoking reduction in midlife reduce mortality risk? Results of 2 long-term prospective cohort studies of men and women in Scotland. Am J Epidemiol. 2013;178(5):770–779
75. Djordjevic MV, Fan J, Ferguson S, Hoffmann D. Self-regulation of smoking intensity. Smoke yields of the low-nicotine, low-‘tar’ cigarettes. Carcinogenesis. 1995;16(9):2015–2021
76. Djordjevic MV, Hoffmann D, Hoffmann I. Nicotine regulates smoking patterns. Prev Med. 1997;26(4):435–440
77. Scherer G. Smoking behaviour and compensation: a review of the literature. Psychopharmacology (Berl). 1999;145(1):1–20
78. Lee PN. The effect of reducing the number of cigarettes smoked on risk of lung cancer, COPD, cardiovascular disease and FEV(1) –a review. Regul Toxicol Pharmacol. 2013;67(3):372–381
79. Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung cancer risk. JAMA. 2005;294(12):1505–1510
80. Teo KK, Ounpuu S, Hawken S, et al; INTERHEART Study Investigators. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet. 2006;368(9536):647–658
81. Yamaguchi N, Mochizuki-Kobayashi Y, Utsunomiya O. Quantitative relationship between cumulative cigarette consumption and lung cancer mortality in Japan. Int J Epidemiol. 2000;29(6):963–968
82. Chapman S, Daube M. Ethical imperatives assuming ENDS effectiveness and safety are fragile. Addiction. 2015;110(7):1068–1069
83. Polosa R, Morjaria J, Caponnetto P, et al. Effect of smoking abstinence and reduction in asthmatic smokers switching to electronic cigarettes: evidence for harm reversal. Int J Environ Res Public Health. 2014; 11(5):4965–4977
84. Hall W, Gartner C, Forlini C. Ethical issues raised by a ban on the sale of electronic nicotine devices. Addiction. 2015;110(7):1061–1067
85. Farsalinos KE, Romagna G, Tsiapras D, Kyrzopoulos S, Voudris V. Evaluating nicotine levels selection and patterns of electronic cigarette use in a group of “vapers” who had achieved complete substitution of smoking. Subst Abuse. 2013;7:139–146
86. Farsalinos KE, Voudris V, Le Houezec J. Risks of attempting to regulate nicotine flux in electronic cigarettes. Nicotine Tob Res. 2015;17(2): 163–164
87. Hajek P, Foulds J, Le Houezec J, Sweanor D, Yach D. Should e-cigarettes be regulated as a medicinal device? Lancet Respir Med. 2013;1(6):429–431
88. Farsalinos KE, Stimson GV. Is there any legal and scientific basis for classifying electronic cigarettes as medications? Int J Drug Policy. 2014;25(3):340–345
89. Federal Register. Proposed Rule by the Food and Drug Administration. Deeming Tobacco Products to be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Regulations on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products. Washington, DC: Federal Register; 2014. Available from: https://www.federalregister.gov/articles/2014/04/25/2014-09491/deeming-tobacco-products-to-be-subject-to-the-federal-food-drug-and-cosmetic-act-as-amended-by-the. Accessed July 23, 2015
90. Official Journal of the European Union. Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006. December 2008. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2008:353:0001:1355:EN:PDF. Accessed July 23, 2015
91. World Health Organization. Ottawa Charter for Health Promotion, 1986. Geneva, Switzerland: WHO. Available from: http://www.euro.who.int/__data/assets/pdf_file/0004/129532/Ottawa_Charter.pdf. Accessed July 28, 2015
92. WHO Europe. What is the Evidence on Effectiveness of Empowerment to Improve Health? København, Denmark: WHO Europe. Available from: http://www.euro.who.int/__data/assets/pdf_file/0010/74656/E88086.pdf. Accessed July 28, 2015
93. Kanwal R, Kullman G, Piacitelli C, et al. Evaluation of flavorings-related lung disease risk at six microwave popcorn plants. J Occup Environ Med. 2006;48(2):149–157.